E76.02 Hurler-Scheie syndrome

Name of the Condition

• Hurler-Scheie syndrome (ICD-10 Code: E76.02)

Summary

Hurler-Scheie syndrome is a rare inherited disorder caused by a deficiency of the enzyme alpha-L-iduronidase, leading to the accumulation of glycosaminoglycans (GAGs) in tissues. This buildup disrupts normal cellular function, resulting in progressive multisystem involvement, including skeletal abnormalities, organ enlargement, and neurological impairment. Early diagnosis and intervention are critical to manage symptoms and slow disease progression.

Causes

Hurler-Scheie syndrome is caused by genetic mutations in the IDUA gene, which encodes the alpha-L-iduronidase enzyme. These mutations impair the enzyme's ability to break down GAGs, leading to their accumulation in cells, tissues, and organs. The condition follows an autosomal recessive inheritance pattern, meaning both parents must carry a mutated gene for a child to be affected.

Risk Factors

• Family history of Hurler-Scheie syndrome or related lysosomal storage disorders.
• Consanguineous relationships (increased risk of recessive inheritance).
• Ethnic or geographic populations with higher carrier rates for IDUA mutations.

Symptoms

• Skeletal abnormalities, such as short stature, joint stiffness, or dysostosis multiplex.
• Organ enlargement (e.g., hepatosplenomegaly).
• Neurological symptoms, including developmental delay, seizures, or cognitive impairment.
• Coarse facial features, clouded corneas, and hearing loss.

Diagnosis

Diagnosis involves clinical evaluation of symptoms, enzyme activity testing to measure alpha-L-iduronidase levels, and genetic testing to identify IDUA gene mutations. Urine tests may detect elevated GAG levels, and imaging studies can assess skeletal or organ abnormalities. Early diagnosis is essential for timely intervention.

Treatment Options

Treatment focuses on managing symptoms and may include enzyme replacement therapy (ERT) to reduce GAG accumulation, hematopoietic stem cell transplantation (HSCT) for some patients, and supportive care for organ dysfunction. Physical therapy, surgery, and medications for pain or respiratory issues may also be used.

Prognosis and Follow-Up

Prognosis varies depending on the severity of symptoms and response to treatment. Regular follow-up with specialists is necessary to monitor organ function, neurological status, and treatment efficacy. Early intervention can improve quality of life and slow disease progression.

Complications

Complications may include severe skeletal deformities, respiratory or cardiac issues, vision or hearing loss, and progressive neurological decline. Untreated, the condition can lead to life-threatening organ dysfunction.

Lifestyle & Prevention

While the condition is inherited, genetic counseling can help families understand risks. Supportive care, such as physical therapy and adaptive devices, may improve daily functioning. No preventive measures exist for those already affected.

When to Seek Professional Help

Seek medical attention if symptoms like developmental delays, organ enlargement, or skeletal abnormalities are observed. Prompt evaluation is crucial for early diagnosis and treatment initiation.

Tips for Medical Coders

Document clinical findings, enzyme test results, and genetic confirmation to support coding. Ensure specificity in documentation to align with the E76.02 code, which distinguishes Hurler-Scheie syndrome from other MPS I subtypes.